NCT05578092 2026-02-19A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayMirati Therapeutics Inc.Phase 1 Terminated64 enrolled
NCT04975256 2024-12-16Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)Mirati Therapeutics Inc.Phase 1 Terminated7 enrolled